In This Article:
ConcertAI has announced an agreement that will allow Bayer to utilise its Translational360 and AI software-as-a-service (SaaS) solutions to expedite clinical development in precision oncology using insights from AI and machine learning (ML).
The multi-year agreement will completely utilise Translational360, a recently introduced integrated research-grade longitudinal clinical molecular database.
This database incorporates de-identified oncology patient data from CancerLinQ, encompassing more than nine million records across all 50 US states.
ConcertAI notes that Translational360 merges genomic, clinical, transcriptomic and whole-slide imaging data from comprehensive molecular testing, offering genomic and phenotypical insights.
Transcriptomics, a key component of biopharma translational sciences, enables researchers to know the molecular mechanisms of diseases, patient response, and inter-patient variability.
These insights are crucial for the development of new therapeutics. By integrating data solutions and AI, the company aims to help choose programmes with the likelihood of success and to design studies that are informed by multi-genomic, transcriptomic, and multi-modal data.
ConcertAI CEO Jeff Elton said: “This partnership furthers causal biological inferences where multi-modal and multi-molecular data can be integrated with AI/ML-based approaches across discovery, translation, and development, accelerating oncology pipelines, allowing our biopharma partners to deliver better medicines faster.
“This partnership builds on a multi-year history of working together and is unique in offering both tissue and liquid biopsy molecular data, allowing insights into patterns of treatment response, acquisition of resistance, AI modelling of likely success and benefit, informing programme priority and clinical study design.”
Bayer Pharma research and development (R&D) Data Science and AI head Sai Jasti said: “By combining ConcertAI’s powerful data solutions with Bayer’s scientific and AI expertise, we aim to enhance the use of real-world data and cutting-edge AI to boost R&D productivity and ultimately deliver transformative precision therapies to those who need them.”
"ConcertAI and Bayer to boost precision oncology with AI and ML insights" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.